Borrelia IgG and IgM Solution

Product Description

The IDS Borrelia IgG and IDS Borrelia IgM assays use chemiluminescence immunoassay (CLIA) technology for the quantitative determination of specific IgG or IgM antibodies to Borrelia burgdorferi sensu lato in human serum or plasma samples on the IDS system.  The results are intended to aid in the assessment of immunity status in patients with signs and symptoms consistent with Lyme disease.

Differentiated serological profile

• Facilitates classification of Lyme borreliosis, based on IgM and/or IgG positivity.
• Helps ensure patients receive rapid results, avoid unnecessary anxiety and additional testing.
• Better patient management
• IDS Borrelia assays are based on recombinant proteins to reduce the cross-reactivity problems, providing higher specificity.
• IDS Borrelia IgM uses two recombinant antigens: OspC, an outer surface protein highly specific for IgM detection (early phase infection), and the VlsE protein. This combination assures a higher diagnostic sensitivity, making this assay a suitable diagnostic tool for the early stages of Lyme disease.
• IDS Borrelia IgG employs the antigen VlsE, an outer surface lipoprotein that plays a key role in the immune response to Lyme disease, leading to increased sensitivity in neuroborreliosis (NB).

Streamlined workflow, rapid results and cost effective

• Ready to use reagents with up to 60 days on-board storage.
• Calibrate once every 28 days with common controls for both IgM and IgG assays.
• Suitable for use with serum or plasma (sodium heparin, sodium citrate, K3-EDTA) samples.
• Decreased number of samples requiring confirmation test when using IgM and IgG assays in combination.